The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Cardiac Safety of Central Nervous System Stimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Abstract
OBJECTIVES. Case reports have raised concerns about the risk of cardiac events associated with central nervous system stimulants for the treatment of attention-deficit/hyperactivity disorder. PATIENTS AND METHODS. This was a retrospective cohort study that used 10 years (July 1994 to June 2004) of Florida Medicaid claims data cross-linked to Vital Statistics Death Registry data. The cohort was composed of all youth 3 to 20 years old who were newly diagnosed with attention-deficit/hyperactivity disorder. Each month of follow-up was classified according to stimulant claims (methylphenidate, amphetamines, and pemoline) as current use (active stimulant claim), former use (time after periods of current use), or nonuse (time preceding the first stimulant claim, including follow-up of youth who were never exposed to stimulants). The study's end points were (1) cardiac death, (2) first hospital admission for cardiac causes or (3) first emergency department visit for cardiac causes. Risks were compared with time-dependent Cox regression analysis adjusting for various cardiac risk factors. RESULTS. During 124932 person-years of observation (n = 55383), 73 youth died, 5 because of cardiac causes. No cardiac death occurred during 42612 person-years of stimulant use. Hospital admissions for cardiac cause occurred for 27 children (8 during stimulant use, 11 during 35671 person-years of former use, and 8 during 46649 person-years of nonuse); and 1091 children visited the emergency department for cardiac causes (8.7 per 1000 person-years). Current stimulant use was associated with a 20% increase in the hazard for emergency department visits when compared with nonuse. No increased risk was found for periods of former use when compared with nonuse. CONCLUSIONS. Incidence rates of cardiac events requiring hospitalization were small and similar to national background rates. Stimulants were associated with an increase in cardiac emergency department visits. More evidence is needed that addresses the long-term risk/benefit of the various treatment options and the effect of other cardiac risk factors and comedications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In children with ADHD, the risk of death from all causes is estimated at 58.4/100,000 patient-years [157]”
From European guidelines on managing adverse effects of medication for ADHD (2011) · cites this paper as [157]
Citations
Cites
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
National Hospital Discharge Survey, 1988
United States Department of Health and Human Services. National Center for Health Statistics (1991) · ICPSR Data Holdings · doi:10.3886/icpsr09521.v1 · Cited by 1,310
National Hospital Discharge Survey, 1988
United States Department of Health and Human Services. National Center for Health Statistics (1991) · ICPSR Data Holdings · doi:10.3886/icpsr09521 · Cited by 1,310
Burt, C. W., & Schappert, S. M. (1997) · PubMed · Cited by 944
Phenylpropanolamine and the Risk of Hemorrhagic Stroke
Kernan, W. N., Viscoli, C. M., Brass, L. M., Broderick, J. P., Brott, T. G., Feldmann, E. G., Morgenstern, L. B., Wilterdink, J. L., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432501 · Cited by 746
National hospital discharge survey: 2004 annual summary with detailed diagnosis and procedure data.
Kozak, L. J., DeFrances, C. J., & Hall, M. J. (2006) · PubMed · Cited by 459
Deaths: leading causes for 2002.
Anderson, R. N., & Smith, B. L. (2005) · PubMed · Cited by 364
ADHD Drugs and Cardiovascular Risk
Nissen, S. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068049 · Cited by 331
Treatment of Attention-Deficit/Hyperactivity Disorder: Overview of the Evidence
Brown, R. T., Amler, R. W., Freeman, W. S., Perrin, J. M., Stein, M. T., Feldman, H. M., Pierce, K., & Wolraich, M. L. (2005) · PEDIATRICS · doi:10.1542/peds.2004-2560 · Cited by 331
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Research works printed but not linked: 1
- Stowe CD, Gardner SF, Gist CC, et al. 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother. 2002;36:1142–1149 · DOI · Paper page
Cited by
Sorted by citations
ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults
Cooper, W. O., Habel, L. A., Sox, C. M., Chan, K. A., Arbogast, P. G., Cheetham, T. C., Murray, K. T., Quinn, V. P., Stein, C. M., Callahan, S. T., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110212 · Cited by 411
European guidelines on managing adverse effects of medication for ADHD
(for the European Guidelines Group), Graham, J., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Döpfner, M., Hamilton, R., Hollis, C., et al. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-010-0140-6 · Cited by 374
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Storebø, O. J., Pedersen, N., Ramstad, E., Kielsholm, M. L., Nielsen, S. S., Krogh, H. B., Moreira-Maia, C. R., Magnusson, F. L., Holmskov, M., Gerner, T., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012069.pub2 · Cited by 321
ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
Habel, L. A., Cooper, W. O., Sox, C. M., Chan, K. A., Fireman, B. H., Arbogast, P. G., Cheetham, T. C., Quinn, V. P., Dublin, S., Boudreau, D. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1830 · Cited by 297
Sudden Death and Use of Stimulant Medications in Youths
Gould, M. S., Walsh, B. T., Munfakh, J. L., Kleinman, M., Duan, N., Olfson, M., Greenhill, L., & Cooper, T. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09040472 · Cited by 253
Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review
Westover, A. N., & Halm, E. A. (2012) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-12-41 · Cited by 141
Cardiovascular Events and Death in Children Exposed and Unexposed to ADHD Agents
Schelleman, H., Bilker, W. B., Strom, B. L., Kimmel, S. E., Newcomb, C., Guevara, J. P., Daniel, G. W., Cziraky, M. J., & Hennessy, S. (2011) · Pediatrics · doi:10.1542/peds.2010-3371 · Cited by 159
Mick, E. O., McManus, D. D., & Goldberg, R. J. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.06.011 · Cited by 136
Martínez-Raga, J., Knecht, C., Szerman, N., & Martínez, M. (2012) · CNS Drugs · doi:10.1007/s40263-012-0019-9 · Cited by 131
Shin, J.-Y., Roughead, E. E., Park, B.-J., & Pratt, N. L. (2016) · BMJ · doi:10.1136/bmj.i2550 · Cited by 122
Dalsgaard, S., Kvist, A. P., Leckman, J. F., Nielsen, H. S., & Simonsen, M. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0020 · Cited by 121
Blood Pressure and Heart Rate Over 10 Years in the Multimodal Treatment Study of Children With ADHD
Vitiello, B., Elliott, G. R., Swanson, J. M., Arnold, L. E., Hechtman, L. T., Abikoff, H., Molina, B. S. G., Wells, K., Wigal, T. L., Jensen, P. S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111705 · Cited by 106
Zhang, L., Yao, H., Li, L., Rietz, E. D., Andell, P., Garcia‐Argibay, M., D'Onofrio, B. M., Cortese, S., Larsson, H., & Chang, Z. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.43597 · Cited by 112
Stimulants and Cardiovascular Events in Youth With Attention-Deficit/Hyperactivity Disorder
Olfson, M., Huang, C. S., Gerhard, T., Winterstein, A. G., Crystal, S., Allison, P. D., & Marcus, S. C. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.11.008 · Cited by 86
Self-citationHammerness, P. G., Perrin, J. M., Shelley-Abrahamson, R., & Wilens, T. E. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.07.018 · Cited by 80
Piloting a mobile health intervention to increase physical activity for adolescents with ADHD
Schoenfelder, E. N., Moreno, M. A., Wilner, M., Whitlock, K. B., & Mendoza, J. A. (2017) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2017.03.003 · Cited by 74
Putukian, M., Kreher, J. B., Coppel, D., Glazer, J. L., Mckeag, D., & White, R. D. (2011) · Clinical Journal of Sports Medicine · doi:10.1097/jsm.0b013e3182262eb1
Winterstein, A. G., Gerhard, T., Kubilis, P. S., Saidi, A. S., Linden, S., Crystal, S., Zito, J., Shuster, J. J., & Olfson, M. (2012) · BMJ · doi:10.1136/bmj.e4627 · Cited by 72
Self-citationCardiovascular Effects of ADHD Therapies
Torres-Acosta, N., O’Keefe, J. H., O’Keefe, C. L., & Lavie, C. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.081 · Cited by 65
Pharmacotherapy for Child and Adolescent Attention-deficit Hyperactivity Disorder
Kaplan, G., & Newcorn, J. H. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2010.10.009 · Cited by 63
Hammerness, P., Wilens, T., Mick, E., Spencer, T., Doyle, R., McCreary, M., Becker, J., & Biederman, J. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.02.008 · Cited by 57
Cardiac Safety of Methylphenidate Versus Amphetamine Salts in the Treatment of ADHD
Winterstein, A. G., Gerhard, T., Shuster, J., & Saidi, A. (2009) · Pediatrics · doi:10.1542/peds.2008-3138 · Cited by 56
Self-citationNasser, A. F., Liranso, T., Adewole, T., Fry, N., Hull, J. T., Chowdhry, F. A., Busse, G. D., Melyan, Z., Cutler, A. J., Findling, R. L., et al. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.01.027 · Cited by 56
Methylphenidate for Giggle Incontinence
Berry, A. K., Zderic, S. A., & Carr, M. C. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.04.085 · Cited by 54
Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder
Huang, Y., & Tsai, M.-H. (2011) · CNS Drugs · doi:10.2165/11589380-000000000-00000 · Cited by 54
Attention-deficit/hyperactivity disorder (ADHD)
Dalsgaard, S. (2012) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0360-z · Cited by 51
Assessment of stimulant use and cardiovascular event risks among older adults
Tadrous, M., Shakeri, A., Chu, C., Watt, J., Mamdani, M. M., Juurlink, D. N., & Gomes, T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.30795 · Cited by 49
Pharmacotherapy of Pediatric Attention-Deficit/Hyperactivity Disorder
Vaughan, B., & Kratochvil, C. J. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.005 · Cited by 46
Chen, C., Yeh, H.-H. H., Chen, K.-H., Chang, I., Wu, E. C., & Lin, K. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0107 · Cited by 43
López, F. A., & Leroux, J. R. (2013) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-013-0106-x · Cited by 43
Cardiovascular Effects of Medications for the Treatment of Attention-Deficit Hyperactivity Disorder
Elia, J., & Vetter, V. L. (2010) · Pediatric Drugs · doi:10.2165/11532570-000000000-00000 · Cited by 35
Warren, A. E., Hamilton, R. M., Bélanger, S. A., Gray, C., Gow, R. M., Sanatani, S., Côté, J.-M., Lougheed, J., LeBlanc, J., Martin, S., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70157-6 · Cited by 34
Long‐QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder
Zhang, C., Kutyifa, V., Moss, A. J., McNitt, S. A., Zaręba, W., & Kaufman, E. S. (2015) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12739 · Cited by 34
Kollins, S. H., Schoenfelder, E. N., English, J. S., Holdaway, A. S., Voorhees, E. E. V., O’Brien, B., Dew, R. E., & Chrisman, A. K. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.07.014 · Cited by 35
Castells, X., Cunill, R., & Capellà, D. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1390-7 · Cited by 41
Methylphenidate and short-term cardiovascular risk
Garcia-Argibay, M., Bürkner, P.-C., Lichtenstein, P., Zhang, L., D’Onofrio, B. M., Andell, P., Chang, Z., Cortese, S., & Larsson, H. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.1349 · Cited by 31
Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?
Hammerness, P. G., Karampahtsis, C., Babalola, R., & Alexander, M. E. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1011620 · Cited by 32
Sayer, G. R., McGough, J. J., Levitt, J., Cowen, J., Sturm, A., Castelo, E., & McCracken, J. T. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0264 · Cited by 28
Pharmacoepidemiological safety studies in children: a systematic review
Osokogu, O. U., Dukanovic, J., Ferrajolo, C., Dodd, C. N., Pacurariu, A. C., Bramer, W. M., t’Jong, G., Weibel, D. M., Sturkenboom, M., & Kaguelidou, F. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4041 · Cited by 23
Black, C., Tagiyeva, N., Helms, P. J. B., & Moir, D. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12645 · Cited by 22
The evidence-based pharmacological treatment of paediatric ADHD
Vaughan, B. S., March, J. S., & Kratochvil, C. J. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000095 · Cited by 25
Cardiovascular Effects of Drugs Used to Treat Attention-Deficit/Hyperactivity Disorder Part 2
Fay, T. B., & Alpert, M. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000234 · Cited by 22
Hamilton, R. M., Rosenthal, É., Hulpke‐Wette, M., Graham, J. G. I., & Sergeant, J. A. (2011) · Cardiology in the Young · doi:10.1017/s1047951111000928 · Cited by 22
Safety of stimulant treatment in attention deficit hyperactivity disorder: part II
Merkel, R. L. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.503238 · Cited by 21
Stimulants and Pediatric Cardiovascular Risk
ZITO, J. M., & Burcu, M. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0239 · Cited by 21
Self-citationStimulant Treatment of ADHD and Risk of Sudden Death in Children
Vitiello, B., & Towbin, K. E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09050619 · Cited by 21
Pre‐existing cardiovascular conditions and pharmacological treatment of adult ADHD
Gerhard, T., Winterstein, A. G., Olfson, M., Huang, C., Saidi, A. S., & Crystal, S. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1931 · Cited by 21
Self-citationWinterstein, A. G. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0379-y · Cited by 18
Self-citationThe use of lisdexamfetamine dimesylate for the treatment of ADHD
Childress, A. C., & Sallee, F. R. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.175 · Cited by 18
The use of attention-deficit hyperactivity disorder medications in cardiac disease
Topriceanu, C., Moon, J., Captur, G., & Perera, B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1020961 · Cited by 21
Pulmonary Aterial Hypertension in an Adolescent Treated with Methylphenidate
Karaman, M. G., Atalay, F., Tufan, A. E., & Erdoğan, A. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0095 · Cited by 16
Gadow, K. D., & Nolan, E. E. (2010) · Journal of Attention Disorders · doi:10.1177/1087054709356405 · Cited by 16
Conway, J. L., Wong, K. K., O’Connell, C. M., & Warren, A. E. (2008) · PEDIATRICS · doi:10.1542/peds.2008-0276 · Cited by 16
Hennessy, S., Schelleman, H., Daniel, G. W., Bilker, W. B., Kimmel, S. E., Guevara, J. P., Cziraky, M. J., & Strom, B. L. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1992 · Cited by 15
Is the use of modafinil, a pharmacological cognitive enhancer, cheating?
Mann, S. P., de Lora, P., Cochrane, T. I., & MITCHELL, C. M. (2018) · Ethics and Education · doi:10.1080/17449642.2018.1443050 · Cited by 12
A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder
Hammerness, P., Zusman, R., Systrom, D., Surman, C., Baggish, A., Schillinger, M., Shelley-Abrahamson, R., & Wilens, T. E. (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.678884 · Cited by 15
Sudden Cardiac Death in Children and Adolescents
Sherwin, E. D., & Berul, C. I. (2017) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2017.07.008 · Cited by 12
Cardiac risk assessment before the use of stimulant medications in children and youth
Bélanger, S., Warren, A., Hamilton, R., Gray, C., Gow, R. M., Sanatani, S., Côté, J.-M., FRCPC, J. L., LeBlanc, J. C., Martin, S. D., et al. (2009) · Paediatrics & Child Health · doi:10.1093/pch/14.9.579 · Cited by 12
Lynch, J. J., Regan, C. P., Stump, G. L., Tannenbaum, P. L., Stevens, J., Bone, A., Gilberto, D. B., Johnson, C. A., Fujino, N., Takenaga, N., et al. (2009) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318195a470 · Cited by 11
Antel, J., Albayrak, Ö., Heusch, G., Banaschewski, T., & Hebebrand, J. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0522-8 · Cited by 11
Zhang, C., Spence, O., Reeves, G. M., & dosReis, S. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.640244 · Cited by 10
Baumeister, T.-B., Wickenbrock, I., & Perings, C. A. (2016) · Drug Safety - Case Reports · doi:10.1007/s40800-016-0035-7 · Cited by 10
Alrwisan, A. A., Wei, Y. J., Brumback, B., Antonelli, P. J., & Winterstein, A. G. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2343 · Cited by 9
Self-citationAmour, M. D. S., O’Leary, D. D., Cairney, J., & Wade, T. J. (2018) · Canadian Journal of Public Health · doi:10.17269/s41997-018-0067-0 · Cited by 9
ADHD Medications and Cardiovascular Risk
Shaw, P. (2011) · JAMA · doi:10.1001/jama.2011.1866 · Cited by 9
Management of a Hyperactive Teen and Cardiac Safety
Sowinski, H., & Karpawich, P. P. (2013) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2013.09.021 · Cited by 8
Bali, V., Kamble, P., & Aparasu, R. R. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.6.486 · Cited by 8
Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
McDonagh, M. S., & Peterson, K. (2011) · Cited by 7
Bali, V., Kamble, P., & Aparasu, R. R. (2015) · Journal of Attention Disorders · doi:10.1177/1087054715608443 · Cited by 7
Attention Deficit Hyperactivity Disorder Screening Electrocardiograms: A Community-Based Perspective
Shahani, S. A., Evans, W. N., Mayman, G. A., & Thomas, V. C. (2013) · Pediatric Cardiology · doi:10.1007/s00246-013-0810-5 · Cited by 7
Drug treatments for attention-deficit hyperactivity disorder in young people
Bates, G. D. L. (2009) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.108.005561 · Cited by 7
Kardiovaskulær risikovurdering ved bruk av AD/HD-medikamenter hos barn
Berg, A., Bråtane, E., Odland, H. H., Brudvik, C. E., Rosland, B., & Hirth, A. (2014) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.13.0565 · Cited by 8
Burcu, M., ZITO, J. M., Safer, D. J., Magder, L. S., dosReis, S., Shaya, F. T., & Rosenthal, G. L. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0121 · Cited by 6
Self-citationKara, T., Mıhçıoğlu, A. M., Yılmaz, S., & Akaltun, İ. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0052 · Cited by 6
Sieluk, J., Palasik, B. N., dosReis, S., & Doshi, P. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4164 · Cited by 6
Yamaguchi, I., & Hanevold, C. D. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0968-1 · Cited by 6
ECG Screening for Sudden Cardiac Death in Children and Adolescents
Saul, J. P., & Gidding, S. S. (2012) · Circulation · doi:10.1161/circulationaha.112.103994 · Cited by 6
Perioperative Outcome of Dyssomnia Patients on Chronic Methylphenidate Use
Stoicea, N., Ellis, T. J., Moran, K. R., Ackermann, W., Wilson, T., Quevedo, E., & Bergese, S. D. (2014) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709614521398 · Cited by 5
Fear of Stimulant Therapy for Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Johnson, M. R. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0117 · Cited by 5
Self-citationPliszka, S. R. (2012) · Wiley eBooks · doi:10.1002/9781119958338.ch6 · Cited by 5
Cardiovascular Considerations for Stimulant Class Medications
Hammerness, P. G., Berger, A. C., Angelini, M. C., & Wilens, T. E. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.02.002 · Cited by 4
Shin, J., Lee, S. H., Shin, S. M., Shin, H. N., & Park, B. (2015) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2015.04.022 · Cited by 4
Suess, M., Chrenka, E. A. B., Kharbanda, E. O., Asche, S. E., O’Connor, P. J., Ekstrom, H. L., & Benziger, C. P. (2023) · Academic Pediatrics · doi:10.1016/j.acap.2023.08.018 · Cited by 4
Attention Deficit/Hyperactivity Disorder (ADHD) in Athletes
Kreher, J. B. (2012) · International Journal of Athletic Therapy & Training · doi:10.1123/ijatt.17.3.15 · Cited by 5
Attention‐Deficit Hyperactivity Disorder and Long‐QT Syndrome: Risky Business
Kaltman, J. R., & Berul, C. I. (2015) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12744 · Cited by 3
Guertin, J. R., LeLorier, J., Durand, M., Gow, R. M., Holbrook, A. M., & Levine, M. (2014) · PubMed · Cited by 3
Alsayouf, H. A., Dyab, L. M., Al-Ghawanmeh, R., Alhawawsha, L. S., Alsarhan, O., Al-Smadi, H., Al‐Taani, G. M., Daoud, A. S., Elsadek, H. E., & Khreisat, W. H. (2024) · Pediatric Reports · doi:10.3390/pediatric16040098 · Cited by 2
Kooij, J. J. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82812-7_4 · Cited by 2
Cautious Reassurance: Cardiovascular Risk in the Context of Stimulant Use
Greenhill, L. L. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.11.013 · Cited by 2
Bélanger, S., Warren, A., Hamilton, R., Gray, C., Gow, R. M., Sanatani, S., Côté, J.-M., Lougheed, J., LeBlanc, J. C., Martin, S. D., et al. (2009) · Paediatrics & Child Health · doi:10.1093/pch/14.9.586 · Cited by 1
Yücel, A., Patel, J. R., & Pise, M. N. (2015) · Journal of Pharmaceutical Health Services Research · doi:10.1111/jphs.12083 · Cited by 1
Stimulant Pharmacotherapy for Adults with ADHD
Hammerness, P. G. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-248-3_5 · Cited by 1
Kooij, J. J. S. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4138-9_4 · Cited by 1
Middleberg, R. A. (2014) · Springer eBooks · doi:10.1007/978-1-61779-403-2_18 · Cited by 1
Central nervous system stimulants and drugs that suppress appetite
Sequeira, R. P. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32001-0 · Cited by 1
Ophir, Y., & Shir-Raz, Y. (2022) · Ethical Human Psychology and Psychiatry · doi:10.1891/ehpp-2022-0011 · Cited by 1
Skinner, J. R., & Muir, C. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.05.015 · Cited by 1
Psychopharmacology in Pediatric Oncology
Pinsky, E. G., & Abrams, A. N. (2012) · Wiley eBooks · doi:10.1002/9781119941033.ch11 · Cited by 1
Place de la pharmaco-épidémiologie dans l’évaluation des médicaments chez l’enfant
Grimaldi‐Bensouda, L., Chalumeau, M., Mikaeloff, Y., & Pons, G. (2008) · Archives de Pédiatrie · doi:10.1016/s0929-693x(08)71923-7 · Cited by 1
Metadata
- Authors
- Winterstein, A. G., Gerhard, T., Shuster, J., Johnson, M., Zito, J. M., & Saidi, A.
- Affiliations
- Department of Healthcare Administration, College of Pharmacy
- Department of Epidemiology, Biostatistics, and Health Policy, General Clinical Research Center
- Gainesville Mental Health Partners, Gainesville, Florida
- University of Maryland, Baltimore (US)
- University of Florida (US)
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2007-12-01
- Volume
- 120
- Issue
- 6
- Pages
- e1494-e1501
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2136389780
- Cited by
- 119
- References
- 32
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 5 · 2015: 11 · 2014: 7 · 2013: 4 · 2012: 21
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PEDIATRICS (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agency for Healthcare Research and Quality (U18HS016097)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- attention deficit hyperactivity disorder, psychostimulants, cardiac safety, methylphenidate, amphetamine, pemoline, cardiovascular mortality, emergency department visits, children and adolescents, stimulant use
- MeSH terms
- Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Child, Preschool, Female, Heart Diseases, Humans, Male, Retrospective Studies, Risk Factors, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review